All
Combination Continues to Show Impressive Outcomes in Melanoma
November 3rd 2017In an interview with CURE, Postow, a medical oncologist specializing in melanoma at Memorial Sloan Kettering Cancer Center, discussed the impressive efficacy seen with combining BRAF and MEK inhibitors for patients with melanoma.
Drug Granted Breakthrough Status to Treat Relapsed or Refractory Myeloma
November 3rd 2017A new drug, GSK2857916, was granted a breakthrough therapy designation by the FDA to treat patients who have relapsed or refractory multiple myeloma, according to GlaxoSmithKline (GSK), the manufacturer of the agent.